Department of Diagnostic & Interventional Radiology of New Hospitals LTD, 12 Krtsanisi, 0114 Tbilisi, Georgia; Department of Radiology, Tbilisi State Medical University (TSMU), Tbilisi, Georgia.
Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA), Universal Scientific Education and Research Network (USERN), Tabriz, Iran.
Acad Radiol. 2021 Aug;28(8):1058-1071. doi: 10.1016/j.acra.2021.04.007. Epub 2021 May 1.
Despite all the benefits and effectiveness of the coronavirus disease 2019 (COVID-19) vaccines mentioned in recent clinical trials, some post-vaccination side effects such as lymphadenopathy (LAP) were observed. The present study reviewed all studies with imaging findings presentation of LAP after COVID-19 vaccination.
We conducted a literature search in online databases, including Scopus, Medline (PubMed), Web of Science, Embase (Elsevier), Cochrane library, and Google Scholar.
A total of 19 studies (68 cases), including 60 (88.2%) females and eight (11.8%) males with a presentation of LAP after COVID-19 vaccination, were reviewed. LAP was identified after first or second dosages of three types of COVID-19 vaccines, including Pfizer-BioNTech (n = 30, 44.1%), Moderna (n = 17, 25%), and Oxford-AstraZeneca (n = 1, 1.5%). In 20 (29.4%) cases, vaccine type was not reported or only reported as mRNA COVID-19 vaccine. The median days of LAP presentation after the first and second dosages of COVID-19 vaccination, were 12 and 5 days, respectively. Most of the LAP imaging findings related to COVID-19 vaccination (n = 66, 97%) were seen from first day to 4 weeks after vaccination. However, LAP remained after 5 and 6 weeks of the first and second dosages of COVID-19 vaccination with decreased lymph nodes' size and residual cortical thickening in two cases.
This review study of cases with LAP-associated COVID-19 vaccination guides radiologists and physicians to rely on patient's clinical context and updated resources to prevent potential disease upstaging and change in therapy.
尽管最近的临床试验提到了 2019 年冠状病毒病（COVID-19）疫苗的所有益处和有效性，但在接种疫苗后观察到了一些不良反应，如淋巴结病（LAP）。本研究回顾了所有与 COVID-19 疫苗接种后 LAP 表现相关的影像学研究。
我们在在线数据库中进行了文献检索，包括 Scopus、Medline（PubMed）、Web of Science、Embase（Elsevier）、Cochrane 图书馆和 Google Scholar。
共回顾了 19 项研究（68 例），包括 60 例（88.2%）女性和 8 例（11.8%）男性在 COVID-19 疫苗接种后出现 LAP。LAP 是在三种 COVID-19 疫苗的第一或第二剂后发现的，包括辉瑞-生物科技（n=30，44.1%）、莫德纳（n=17，25%）和牛津-阿斯利康（n=1，1.5%）。在 20 例（29.4%）病例中，未报告或仅报告疫苗类型为 mRNA COVID-19 疫苗。COVID-19 疫苗接种后 LAP 出现的中位数天数分别为第一和第二剂量后 12 天和 5 天。大多数与 COVID-19 疫苗接种相关的 LAP 影像学表现（n=66，97%）是在接种疫苗后第 1 天至第 4 周内发现的。然而，在 COVID-19 疫苗接种的第一和第二剂量后 5 周和 6 周，两个病例的淋巴结大小减小，皮质增厚残留。
本研究回顾了与 COVID-19 疫苗接种相关的 LAP 病例，指导放射科医生和医生根据患者的临床背景和最新资源进行判断，以预防潜在的疾病升级和治疗改变。
